Diamond Hill Capital Management Inc. Reduces Stock Holdings in Illumina, Inc. $ILMN

Diamond Hill Capital Management Inc. reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 9.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 342,957 shares of the life sciences company’s stock after selling 36,824 shares during the period. Diamond Hill Capital Management Inc.’s holdings in Illumina were worth $32,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Next Capital Management LLC bought a new position in Illumina in the 2nd quarter worth about $341,000. CWM LLC grew its stake in shares of Illumina by 112.9% during the second quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock valued at $7,319,000 after buying an additional 40,676 shares during the last quarter. Generali Asset Management SPA SGR increased its stake in Illumina by 51.6% in the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after purchasing an additional 7,574 shares during the period. Andra AP fonden raised its holdings in Illumina by 426.3% during the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after buying an additional 83,017 shares during the last quarter. Finally, Aaron Wealth Advisors LLC lifted its position in Illumina by 342.6% during the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after buying an additional 8,109 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $119.72 on Friday. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53. The firm has a market capitalization of $18.29 billion, a P/E ratio of 21.97, a PEG ratio of 1.99 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The business has a fifty day moving average of $138.43 and a 200 day moving average of $116.26.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 32.33%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the business posted $0.95 earnings per share. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Illumina reported GAAP/non‑GAAP EPS of $1.35 (beat) and revenue of $1.16B (beat), with ex‑China growth stronger; management highlighted improving margins. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: FY‑2026 guidance mostly in line or better than Street — Illumina guided revenue to $4.5–$4.6B (above some estimates) and non‑GAAP EPS to $5.05–$5.20, signaling modest growth after recent year flatness. The guidance incorporates the SomaLogic acquisition and expected dilution. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: Underlying business trends cited as constructive — analysis points to clinical consumables growth, expansion into multiomics, and margin momentum that could support higher recurring revenue over time. ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum
• Neutral Sentiment: Call/transcript color: management reiterated strategy and provided details on growth drivers and the SomaLogic deal; read the call for guidance assumptions and segment commentary. Illumina Q4 2025 earnings call transcript Seeking Alpha transcript
• Negative Sentiment: Investors disappointed by FY‑2025 flat revenue and cautious tone — FY‑2025 revenue was essentially flat versus prior year, and some investors focused on slower organic growth and the near‑term dilution/costs from the SomaLogic acquisition, prompting selling pressure despite the EPS beat and guidance. Illumina shares tumble as flat revenue disappoints investors
• Negative Sentiment: Analyst/read‑through risk: even with some bullish commentary, markets may be repricing expectations for near‑term top‑line acceleration given mixed signals between margin upside and tepid full‑year growth. Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN)

Analysts Set New Price Targets

Several brokerages recently issued reports on ILMN. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Guggenheim upped their price target on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Robert W. Baird set a $137.00 price objective on Illumina in a research report on Friday. Evercore ISI set a $150.00 target price on Illumina in a research note on Friday. Finally, JPMorgan Chase & Co. lowered their price target on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research report on Friday. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and an average target price of $130.00.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.